Rockefeller University researchers have reported encouraging clinical outcomes from a Phase I trial of 2141.V11, an Fc-optimized CD40 agonistic antibody administered intratumorally to metastatic cancer patients. The agent demonstrated systemic antitumor immunity with tumor shrinkage observed in half of the treated patients, including complete remission in melanoma and breast cancer cases. This represents a significant advancement in overcoming prior toxicity and efficacy challenges associated with CD40 agonists in human cancer therapy.